Patient perspectives on the use of digital medical devices and health data for AI-driven personalised medicine in Parkinson's Disease.

INTRODUCTION

Parkinson's Disease (PD) affects around 8.5 million people currently with numbers expected to rise to 12 million by 2040. PD is characterized by fluctuating motor and non-motor symptoms demanding accurate monitoring. Recent advancements in digital medical devices (DMDs) like wearables and AI offer promise in addressing these needs. However, the successful implementation of DMDs in healthcare relies on patients' willingness to adopt and engage with these digital tools.

METHODS

To understand patient perspectives in individuals with PD, a cross-sectional study was conducted as part of the EU-wide DIGIPD project across France, Spain, and Germany. Multidisciplinary teams including neurodegenerative clinics and patient organizations conducted surveys focusing on (i) sociodemographic information, (ii) use of DMDs (iii) acceptance of using health data (iv) preferences for the DMDs use. We used descriptive statistics to understand the use of DMDs and patient preferences and logistic regression models to identify predictors of willingness to use DMDs and to share health data through DMDs.

RESULTS

In total 333 individuals with PD participated in the study. Findings revealed a high willingness to use DMDs (90.3%) and share personal health data (97.4%,) however this differed across sociodemographic groups and was more notable among older age groups (under 65 = 17.9% vs. over 75 = 39.29%,  = 0.001) and those with higher education levels less willing to accept such use of data (university level = 78.6% vs. 21.43% with secondary level,  = 0.025). Providing instruction on the use of DMDs and receiving feedback on the results of the data collection significantly increased the willingness to use DMDs (OR = 3.57, 95% CI = 1.44-8.89) and (OR = 3.77, 95% CI = 1.01-14.12), respectively.

CONCLUSION

The study emphasizes the importance of considering patient perspectives for the effective deployment of digital technologies, especially for older and more advanced disease-stage patients who stand to benefit the most.